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Abstract
Background: Rheumatic diseases are associated with an increased fracture risk. The tissue level characteristics
of the bone involvement in children have not been well elucidated. Our objectives were to describe the bone
micro-architectural characteristics in children with rheumatic diseases on chronic glucocorticoids, and to determine
associations between micro-architectural findings with clinical and radiological variables.
Methods: Children on chronic glucocorticoids for an underlying rheumatic disease were referred for evaluation of
bone fragility given the presence of vertebral compression fractures. A trans-iliac bone biopsy was performed as
part of the clinical assessment. Histomorphometric analysis and quantitative backscattered electron imaging (qBSE)
of the biopsy samples were undertaken.
Results: Data of 15 children (14.0 ± 3.2 years) with a duration of glucocorticoid exposure of 6.2 ± 4.1 years and
average prednisone dose of 14.1 ± 6.2 mg/m2/day were assessed. Histomorphometric analyses demonstrated
significant decrease in trabecular thickness (p = 0.01), osteoid thickness (p < 0.01), osteoblast surface (p = 0.02) and
increase in trabecular separation (p = 0.04) compared to published age-matched normative data. Severity of the
trabecular deficit was correlated to glucocorticoid dose, height and body mass index Z score, but not bone mineral
density or measures of disease activity. Using qBSE to measure bone mineralization, the subjects were shown to
have a heterogeneous and hypermineralized profile, with higher cumulative glucocorticoid dose being associated
with greater mineralization (p < 0.01).
Conclusions: In children with rheumatic diseases presenting with vertebral fractures, there is evidence of abnormal
bone matrix mineralization and impairments of bone micro-architecture that correlate to glucocorticoid dose.
Keywords: Glucocorticoids, Juvenile idiopathic arthritis, Systemic lupus erythematosis, Osteoporosis, Bone
histomorphometry, Bone mineralization
Background
Children and adolescents with rheumatic diseases, such
as systemic lupus erythematosis (SLE) and juvenile
idiopathic arthritis (JIA) are recognized to be at risk for
impaired bone health. In those who develop overt osteo-
porosis, multiple risk factors are implicated, including
increased concentrations of inflammatory cytokines,
diminished nutrition, physical activity and muscle bulk
[1, 2]. Use of glucocorticoids, in particular, is also known
to compromise bone mass, quality and strength [3]. As a
consequence, in children with rheumatic conditions, a 10
to 30 % prevalence rate of vertebral fractures has been re-
ported [4–7], with a 6 % incidence of vertebral fractures
within 12 months of glucocorticoid initiation [8].
Bone mineral density (BMD) as measured by dual-
energy x-ray absorptiometry (DXA), is one of the most
common tools used to assess bone health. Low BMD
is associated with an increased risk for fractures in other-
wise healthy children [9]. Children with rheumatic dis-
eases including SLE and JIA have been shown to have
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reduced BMD compared to healthy age-matched controls
[1, 10–12]. Decreased lumbar spine BMD Z score in the
first 6 months of initiation of glucocorticoid treatment has
been demonstrated to be an important predictor for in-
creased vertebral fracture risk [13]. DXA has, however,
limitations in the assessment of bone health in pediatric
cohorts given that the results are influenced by bone size
[14]. In addition bone strength is determined not only by
bone density but also by the underlying bone quality and
micro-architecture.
Histomorphometric analysis of trans-iliac bone samples
allows characterization of bone microarchitecture includ-
ing bone quantity, structure and metabolism. Histomor-
phometric studies in adults with rheumatoid arthritis have
shown evidence of reduced trabecular bone volume with
decreased trabecular thickness and bone turnover [15, 16].
Moreover, in adult cohorts, vertebral fractures have
been demonstrated to relate to trabecular bone micro-
architecture independent of the bone density [17].
The mineral content of bone has similarly been demon-
strated to be an important determinant of bone stiffness
and strength [18]. The degree and heterogeneity of bone
mineralization can be measured from trans-iliac bone
samples using quantitative backscattered electron imaging
(qBSE). Deviations in bone mineralization have been
demonstrated in patients with bone fragility, such as in
children with osteogenesis imperfecta [19] and adults with
postmenopausal osteoporosis [20], but have not been
assessed to date in patients with rheumatic diseases.
Studies of bone histomorphometry and mineralization
in pediatric patients treated with glucocorticoids have
contributed to the understanding of underlying pathology
and clinical factors with the potential to predict severity of
bone disease [21, 22]. Given these features have not to
date been described in pediatric rheumatalogical patients,
the aims of this pilot study were therefore to characterize
bone histomorphometry and mineralization in a small
cohort of children with rheumatic diseases and to assess
associations between clinical and radiological indices to
bone micro-architecture.
Methods
All patients with a rheumatic disease who had been re-
ferred to the Bone Health Clinic at the Hospital for Sick
Children, Toronto between 2003 and 2011 and who had
undergone a trans-iliac bone biopsy were included in
this retrospective descriptive analysis. Patients had been
referred to the clinic for assessment of bone health be-
cause of the finding of at least one vertebral compres-
sion fracture. All patients were on calcium and vitamin
D supplements and had undergone baseline investiga-
tions including biochemical assessment of parameters of
calcium homeostasis, as well as spinal radiographs and
DXA. The bone biopsy was undertaken as part of the
clinical evaluation for symptomatic osteoporosis. Exclu-
sion criteria included children with impaired renal func-
tion or other chronic medical conditions (other than
their rheumatic disease) that could affect bone health.
This study was approved by the Hospital for Sick Chil-
dren’s Research Ethics Committee.
Clinical data
Information was collected from the patients’ records re-
garding their underlying rheumatic disease, including age
of diagnosis, duration of symptoms and treatment. All
children were on glucocorticoid treatment (prednisone) at
the time of the bone biopsy. Duration of glucocorticoid
treatment, as well as cumulative and average daily dose
was documented. All glucocorticoid doses were expressed
as milligrams per body surface area (mg/m2) in prednis-
one equivalents. Clinical data including age, height and
weight were collected from the time of the trans-iliac bone
biopsy. Height was measured with a wall-mounted stadi-
ometer to the nearest 0.1 cm and weight was taken on an
electric digital scale to the nearest 0.1 kg. Height, weight
and body mass index (BMI) [weight (kg)/height (m)2] z-
score were calculated using reference data provided by the
Centre for Disease Control 2000 standardized reference
charts. Pubertal development was assessed according to
Tanner criteria [23, 24]. As a measure of functional status
of the subjects at the time of the bone biopsy, the Child-
hood Health Assessment Questionnaire (CHAQ) score
was recorded. The CHAQ score is a validated, reliable tool
for measuring functional status in children with juvenile
idiopathic arthritis [25], and has also been demonstrated
to reflect disease activity in other rheumatological condi-
tions [26, 27]. CHAQ scores range from 0 (indicating no
disability) to 3 (severe disability).
Biochemistry
Biochemical markers taken at the time of the biopsy
were recorded. Serum calcium, phosphate and alkaline
phosphatase were measured by spectophotometry using
the VITROS 950 Chemistry System (Johnson and Johnson
Ortho-Clinical Diagnostics, Rochester, NY). Serum intact
parathyroid hormone (PTH) was measured by IMMU-
LITE chemoiluminescent immunometric assay (Siemens
Healthcare Diagnostics, Deerfield, IL). Serum 25 hydroxy-
vitamin D (25(OH)D) was measured by high-performance
liquid chromatography tandem mass spectroscopy or
radioimmunoassay (DiaSorin S,p,A, Saluggia, Italy).
Erythrocyte sedimentation rate (ESR) was used as a bio-
chemical marker of rheumatological disease activity.
Radiological studies
Lumbar spine (L1 to L4) areal BMD was measured by
dual-energy X-ray absorptiometry (DXA) in the anterior-
posterior direction (Lunar Prodigy; General Electric;
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Madison, WI, USA). Compressed lumbar vertebrae were
excluded from the analysis. To account for bone size
and height, bone mineral apparent density (BMAD) was
derived using the method proposed by Kroger et al., where
by BMAD=BMD × [4/(π x width)] [28]. Areal BMD and
BMAD values were transformed into Z scores using the
equipment specific age and sex-adjusted Canadian refer-
ence values for areal BMD and published reference data
for BMAD [29].
Standard lateral thoracic and lumbar spine radiographs
were obtained in an upright position. All radiographs
were assessed for vertebral morphology and loss of verte-
bral height. Morphology was determined using the Genant
semi-quantitative method by measuring the posterior,
mid-body and anterior vertebral body height ratios as de-
scribed previously [30]. Significant vertebral compression
was defined as a height loss of greater than 20 %. Vertebral
bodies with evidence of compression were assigned a se-
verity score; grade 1 =mild (loss of height of > 20 to 25 %),
grade 2 =moderate (loss of height of > 25 to 40 %), and
grade 3 = severe (loss of height of > 40 %) [30].
Trans-iliac histomorphometry
Utilizing ultrasound and fluoroscopic guidance, full
thickness transiliac bone biopsies were obtained with a
Rochester biopsy device under general anaesthetic from
a site located 2 cm below and behind the anterior super-
ior iliac spine for static histomorphometry. Informed
consent was obtained from all subjects. Biopsy preparation
and static histomorphometric analyses were performed as
previously described [31]. In brief, the specimens were
placed in 70 % ethanol, then dehydrated and embedded in
polymethylmethacrylate. Histomorphometric parameters
were evaluated in undecalcified sections treated with
Goldner’s trichrome or Von Kossa stain. The total tra-
becular area was analyzed as serial fields using the Lietz
Bioquant morphometry system (Bioquant Nova Prime,
Version 6.50.10). Bone histology was reported using the
terminology established by the Nomenclature Committee
of the American Society of Bone and Mineral research
[32]. Results were converted to percentage scores com-
pared to published reference age and gender matched
controls [31].
Bone mineralization
The embedded iliac crest biopsy blocks were used for
evaluation of bone mineralization density distribution
(BMDD) using quantitative backscattered electron im-
aging (qBSE). The blocks were cut, polished, carbon-
coated and imaged using backscattered electron imaging
(solid state BSE detector, FEI Company, Hillsboro, OR,
USA) on a FEI XL30 ESEM. This technique allows
quantification of the intensity of the backscattered elec-
tron signal from the surface of a sectioned bone by
calibration of the brightness and contrast. Histograms of
the grey level distribution were created for the trabecular
bone of the iliac crest samples, with a range of grey
levels from 0 to 255. Increasing brightness corresponds
with increasing mineralization [33]. The signal is propor-
tional to the weight fraction of calcium in the embedded
bone tissue. Two parameters were derived for statistical
analysis; mineralization peak, the peak position on the
histogram which indicates the most frequently occurring
grey level in the bone area, and the full width at half-
maximum height (FWHMH) of the bone mineralization
histogram curve which describes the mineral heterogen-
eity of the sample.
Statistical analysis
The data were analyzed using SPSS 21.0 for windows
(SPSS Inc, Chicago, IL, USA). Anthropometry and densi-
tometry Z scores were tested for significant deviation
from zero using the one-sample t-test. Differences in
histomorphometric measurements between the cohort
and published normative data were assessed by comparing
the subject’s results as expressed as a percentage of the ref-
erence mean versus 100 % using one-sample t-tests. Corre-
lations between histomorphometric, bone mineralization
and clinical variables were evaluated with Pearson and
Spearman rank correlations. No adjustment for multiple
comparisons was made. Statistical significance was in-
ferred with a P value less than 0.05.
Results
Cohort clinical characteristics
Fifteen children (12 females) with a mean age of 14.0 ±
3.2 years were included in this analysis. Eight of the
children had a diagnosis of SLE, 5 systemic JIA and 2
had a systemic vasculitis. The clinical characteristics of
the cohort are displayed in Table 1. All patients had
been commenced on glucocorticoid treatment within
2 months of clinical diagnosis.
Serum concentrations of calcium, phosphate, parathy-
roid hormone and creatinine were within the normal
range for all subjects at time of the biopsy. The median
25(OH)D concentration was 69.5 (43 to 118) nmol/L, and
only one patient had a concentration less than 50 nmol/L.
Mean alkaline phosphatase was 133.9 ± 48.2 IU/L, with 6
patients having concentrations below the normal refer-
ence range for age and gender. ESR was mildly raised
in most subjects with a median concentration of 13
(range 1 to 57) mm/h.
Radiological measures of bone health
Twelve of the fifteen patients were investigated for ver-
tebral compression fractures due to the onset of back
pain, while the remaining three had an X-ray of their
spine performed following the finding of a lumbar BMD
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Z score less than −2 on DXA. There were a total of 68
vertebral fractures within the entire cohort, with the ma-
jority involving the thoracic region (71 %). Almost 50 %
of the cohort had fractures involving 5 or more of the
vertebrae, with over half of the subjects having grade 2
severity vertebral height loss (loss of height of > 25 to
40 %) (Table 1). Greater number of vertebral compres-
sion fractures was associated with higher BMI Z score
(r = 0.78, p < 0.01). None of the patients had a history of
peripheral fractures. Greater severity of vertebral height
loss was associated with higher cumulative glucocorticoid
dose (r = 0.56, p = 0.03), longer disease duration (r = 0.60,
p = 0.02) and higher CHAQ score (r = 0.60, p = 0.02).
The lumbar spine areal BMD and BMAD were signifi-
cantly below results expected in healthy subjects of the
same age and gender (p < 0.001). There was, however, a
spectrum of values, and 6 of the 15 of the subjects had a
lumbar spine BMAD Z score greater than −2.0. Lower
lumbar spine BMAD Z score was associated with greater
average glucocorticoid dose (r = −0.50, p = 0.04), but not
cumulative dose or duration of glucocorticoids. There
was no significant association between number or sever-
ity of vertebral compression factures and BMD.
Trabecular iliac bone histomorphometry
Iliac bone histomorphometry demonstrated evidence of
thinning of the trabecular with increased separation, al-
though preservation of the trabecular number (Table 2).
Bone formation activity was decreased with low markers
of osteoid formation and percentage of osteoblast-covered
surface. There was no significant difference in histomor-
phometric values in the subjects with JIA compared to
those with SLE.
Univariate analysis showed that higher average gluco-
corticoid dose was associated with greater deficits in
both bone structural and formation parameters. (Table 3).
In particular, the amount of osteoblast surface per bone
surface percentage strongly associated with both dose
and duration of glucocorticoids. Systemic clinical effects
of glucocorticoids (higher BMI and lower height Z
score), also correlated with histomorphometric parame-
ters. Lower bone volume and osteoblast surface associ-
ated with a greater number of vertebral compression
fractures. There was no association between bone histo-
morphometry with lumbar spine areal BMD or BMAD
Z scores, 25(OH)D or ESR concentrations.
The rheumatological patients had a mineralization
peak of 167.4 ± 20.5 and a FWHMH of 34.3 ± 7.2. The
bone mineralization of the patient cohort was compared
to published normative values for healthy children [34].
The rheumatological patients had a shift in the mineral
distribution towards a more hypermineralized profile
(p <0.001) and had a greater heterogeneity in the
mineralization distribution (p < 0.01). Greater cumulative
glucocorticoid dose (r = 0.71, p < 0.01), lower histomor-
phometric bone formation parameters (r = −0.7, p < 0.01)
and lower serum alkaline phosphatase concentration
were associated with a more hypermineralized profile
(r = −0.52, p = 0.04). Bone mineralization variables did
not related to age, anthropometry or lumbar spine bone
mineral density.
Discussion
This study demonstrated that children with rheumatic
diseases on chronic glucocorticoids who presented with
vertebral fractures, have evidence of significantly de-
creased bone structural and formation histomorphometric
indices compared to healthy age matched peers. The bone
mineralization findings revealed greater heterogeneity of
Table 1 Clinical characteristics of the study cohort
Clinical variable Results (n = 15)
Age at time of bone biopsy (years) 14.0 ± 3.2
Age at diagnosis of rheumatologic disease (years) 7.6 ± 3.6
Anthropometry at time of bone biopsy
Height Z score −2.3 ± 1.4
Weight Z score −0.2 ± 1.4
Body mass index Z score 0.8 ± 1.2




Functional ability at time of bone biopsy
(CHAQ score)
0.25 (0 to 1.87)a
Erythrocyte sedimentation rate (mm/h) 13 (1 to 57)a
Glucocorticoid treatment
Duration of glucocorticoid treatment (years) 6.2 ± 4.1
Cumulative glucocorticoid dose (mg/m2)c 29134 ± 29410
Average glucocorticoid dose (mg/m2/day)c 14.1 ± 6.2
Number of vertebral fractures (number of subjects)
1 vertebral fracture 5 (33 %)
2 to 4 vertebral fractures 3 (20 %)
≥ 5 vertebral fractures 7 (47 %)
Fracture severity (number of subjects)d
Grade 1 3 (20 %)
Grade 2 10 (67 %)
Grade 3 2 (13 %)
Lumbar spine areal BMD Z score −3.4 (−5.5 to −1.7)a
Lumbar spine BMAD Z score −2.9 (−4.1 to −0.9)a
Serum 25(OH)D (nmol/L) 69.5 (43 to 118)a
Results are expressed as mean ± standard deviation unless otherwise indicated
amedian (range)
bpre-pubertal: Tanner stage 1, mid-pubertal: Tanner stage 2 and 3, post-
pubertal: Tanner stage 4 and 5
creported in prednisone equivalents
dpatients with multiple vertebral fractures were graded according to the
highest severity score
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mineralization as well as a significant shift towards hyper-
mineralization within the trabecular bone.
Patients with rheumatic conditions are at increased
risk for bone fragility and fractures. [5–7]. Higher
glucocorticoid dose have been shown to correlate with
the presence of vertebral fractures [7, 8]. Similarly in
our study, those children with greater cumulative
glucocorticoid dose had a more severe grade of verte-
bral height loss. The results from this study add to this
literature by demonstrating that the underlying histo-
morphometric deficits in trabecular bone in these chil-
dren also relate to glucocorticoid dose. In our cohort,
structural and formation parameters were lower than
the age-specific reference range. Adults with rheuma-
toid arthritis have been shown to have evidence of de-
creased trabecular bone volume and turnover [15, 35].
Reduced trabecular thickness and osteoblast surface
have similarly been found in other cohorts of children
treated with glucocorticoids such as those with Duchene
muscular dystrophy and steroid dependent nephrotic syn-
drome [21, 22]. Unlike, however, the histomorphometry
results from the pediatric patients with nephrotic syn-
drome, our subjects did not have evidence of osteomal-
acia, as seen by the reduced osteoid thickness and volume.
The primary effect of the glucocorticoid treatment in our
subjects would appear to be through the reduction in
bone formation decreasing osteoblastogenesis, increasing
osteoblast apoptosis and inhibiting osteoblast production
of bone matrix [36–38].
As well as the relationship between glucocorticoid dose
and trabecular bone deficit, we were able to demonstrate
that those children with more pronounced systemic ef-
fects from their steroid treatment (specifically reduced
height and increased BMI Z score) have lower trabecular
thickness and osteoblast surface. This association between
increased BMI and greater bone fragility has also been
demonstrated in a prospective study of children with
rheumatic conditions which assessed determinants of
vertebral fractures [13]. Combined, these findings would
support that clinicians should have heightened vigilance
around bone health screening in those rheumatological
patients with systemic glucocorticoid effects.
Table 3 Clinical correlates with trans-iliac histomorphometry









Average glucocorticoid dose (mg/m2/day) −0.61 (p = 0.01) −0.66 (p < 0.01) −0.61 (p = 0.01) −0.88 (p < 0.01)
Cumulative glucocorticoid dose (mg/m2) −0.32 (p = NS) −0.25 (p = NS) −0.39 (p = NS) −0.89 (p < 0.01)
Glucocorticoid duration −0.11 (p = NS) −0.17 (p = NS) −0.30 (p = NS) −0.52 (p = 0.04)
Height Z score 0.35 (p = NS) 0.50 (p = 0.04) 0.43 (p = NS) 0.70 (p < 0.01)
BMI Z score −0.33 (p = NS) −0.29 (p = NS) −0.19 (p = NS) −0.70 (p < 0.01)
Number of vertebral compression fractures −0.51 (p = 0.04) −0.23 (p = NS) −0.43 (p = NS) −0.87 (p < 0.01)
Lumbar spine areal BMD Z score 0.19 (p = NS) 0.26 (p = NS) 0.20 (p = NS) 0.40 (p = NS)
Lumbar spine BMAD Z score 0.13 (p = NS) 0.05 (p = NS) −0.10 (p = NS) 0.25 (p = NS)
Data are Pearson’s correlation r (p value). All significant results (p < 0.05) are highlighted in bold. NS = not significant
aHistomorphometry results were converted to percentiles compared to published age matched normative data prior to analysis
Table 2 Static histomorphometric results from trans-iliac bone biopsies
Raw results % Reference meana p valueb
Structural parameters
Bone volume (BV/TV) (%) 20.9 ± 7.0 82.9 ± 28.9 0.06
Trabecular number (Tb. N) (#/mm) 1.78 ± 0.4 92.8 ± 36.1 0.54
Trabecular thickness (Tb. Th) (μm) 107 ± 21 76.0 ± 22.1 <0.01
Trabecular separation (Tb. Sp) (μm) 505 ± 101 115.9 ± 21.3 0.04
Formation parameters
Osteoid surface (OS/BS) (%) 16.5 ± 3.7 83.0 ± 16.2 0.01
Osteoid volume (OV/BV) (%) 1.8 ± 0.6 88.8 ± 18.7 0.06
Osteoid thickness (O.Th) (μm) 4.6 ± 0.6 71.9 ± 18.6 <0.01
Osteoblast surface (Ob.S/BS) (%) 5.0 ± 2.7 62.8 ± 21.0 <0.01
All data is presented as mean ± standard deviation
aAverage of percentage of age-matched reference mean published previously
bHistomorphometry results (structural and formation parameters) were converted to percentiles compared to published age matched normative data prior to analysis
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In addition to structural and formation deficits, chil-
dren with rheumatic diseases on glucocorticoids have
significant differences in trabecular bone mineralization
compared to healthy controls. Trabecular bone consists
of individual osteons and bone packets that have differ-
ent mineral contents depending on when they were pro-
duced during the (re) modeling cycle. During secondary
mineralization the mineral content of these bone packets
increases with time as free water in the bone matrix is
replaced by mineral [18]. Bone mineralization as mea-
sured by qBSE quantifies the degree and heterogeneity
of mineralization across the cross-sectional area of the
trans-iliac bone biopsy, and is determined by bone turn-
over rate and by the time course of mineral accumula-
tion within the bone matrix [18]. In our subjects, the
shift in the bone mineralization towards a more hyper-
mineralized profile would be consistent with decreased
bone turnover leading to a greater percentage of miner-
alized bone packets. The inverse association between
mineralization peak and histomorphometric bone forma-
tion parameters as well as serum bone turnover marker
alkaline phosphatase, would support this finding. The
increased heterogeneity of the matrix mineralization is
also likely a result of a significant decrease in bone turn-
over. In experimental models, decreased bone turnover
has been shown to lead to increased heterogeneity in bone
mineralization [39]. Increased degree of mineralization
through decreased bone remodeling is probably a signifi-
cant contributor to the underlying bone fragility in our
subjects. In other conditions, bone hypermineralization
has been demonstrated to contribute to bone brittleness
and tendency to fracture [40, 41].
BMD as measured by DXA is a commonly used screen-
ing tool to assess bone health in children on chronic glu-
cocorticoids. A meta-analysis demonstrated a difference of
−0.18 [−0.25; −0.1] g/m2 lower spine BMD in children
with JIA on glucocorticoids compared to healthy controls
[42]. Similarly we demonstrated an association between
average daily glucocorticoid dose and BMAD Z score.
While low bone mass in pediatric patients has been de-
fined by a BMD Z score of less than or equal to −2 [43],
only 60 % of our cohort, all of whom had vertebral com-
pression fractures, had a lumbar spine BMAD Z score that
met this criteria. We also did not find a correlation of ei-
ther lumbar spine areal BMD or BMAD to the histomor-
phometric or mineralization indices. While the density of
bone is measured in BMD values, our findings would sug-
gest that DXA BMD values do not always reflect some of
the other underlying pathological mechanisms that gluco-
corticoids have on bone. In addition clinical variables such
as short stature, delayed skeletal maturation, ethnicity and
lean body mass can confound BMD results [43, 44]. The
lack of association of bone histomorphometry to BMD
highlights the limitations of relying on BMD values alone
to evaluate bone health in children with chronic diseases.
Given its invasive nature, trans-iliac bone biopsies are not
suitable as a bone health screening tool, but should be
limited to those patients who appear to have severe bone
fragility out of keeping of their medical history or bone
health risk factors. Instead, yearly lateral thoracolumbar
spine X-rays to assess for vertebral height loss should be
used in conjunction with BMD values to screen children
with rheumatic conditions on glucocorticoids for evidence
of bone fragility.
The treatment of bone fragility in children with rheum-
atic conditions is challenging, in part because of limited
therapeutic options in the pediatric age range. Given
higher rates of vitamin D deficiency in children with
rheumatic conditions [45, 46], ensuring adequate vitamin
D and calcium intake to maintain bone mineralization is
an important first line therapy, although may not be suffi-
cient to help prevent fragility fractures [13]. The use of
biologic agents in JIA, has been demonstrated to help
facilitate new bone formation after discontinuation of glu-
cocorticoids [47]. These effects are however, attenuated in
those patients who remain on glucocorticoids [48].
Bisphosphonates have been shown to improve BMD in
children with secondary osteoporosis [49, 50]. Our find-
ings of low baseline osteoblast activity in children on
chronic glucocorticoids, emphasizes the need for cautious
use of anti-resorptive agents such as bisphosphonates,
which can lead to further suppression of bone turnover
[21]. Consideration of commencing bisphosphonate ther-
apy should be reserved for those patients presenting with
significant fragility fractures or bone pain.
There are limitations to our study that deserve consid-
eration, in particular the small number of subjects in-
cluded in this analysis. Given the small subject numbers
further data from a larger number of subjects is needed
to confirm the findings from this pilot study. In addition
the subjects in our study presented with a significant
degree of bone fragility and vertebral compression frac-
tures. It is uncertain to what degree similar histomor-
phological and mineralization deficits would be seen in a
cohort of asymptomatic children on equivalent gluco-
corticoid doses. While we demonstrated a linear rela-
tionship between glucocorticoid dose and trabecular
structural deficits, we cannot comment as to whether
there is a threshold glucocorticoid dose below which
there would not be a significant detrimental effect on
bone quality. Only static and not dynamic histomorpho-
metry was able to be performed, as the subjects had not
received tetracycline prior to the biopsy being taken.
Conclusions
In conclusion, our results from this small pilot study
demonstrate that children with rheumatic diseases on
chronic glucocorticoid treatment who present with
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vertebral compression fractures have evidence of de-
creased trabecular bone volume and formation with
increased and more heterogeneous mineralization. The
association between glucocorticoid dose to the bone
micro-architectural deficits, highlights the importance
of decreasing the steroid dose in chronic disease states
where possible. Treatment with bisphosphonates is some-
times used in children with glucocorticoid induced osteo-
porosis, however can lead to further suppression of bone
formation [21]. Our findings support the need for further
research in anabolic treatment options for children, in
order to address the underlying bone pathology.
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